title: Tailoring of drug delivery of 5-fluorouracil to the colon via a mixed film coated unit system.
abstract: The study was carried out to establish the effectiveness of a mixed film composed of ethylcellulose/Eudragit S100 for colonic delivery of 5-flourouracil (5-FU). Tablets cores containing 5-FU were prepared by direct compression method by coating at different levels (2-9%, m/m) with a non-aqueous solution containing ethylcellulose/Eudragit S100. Coated tablets were studied for the in vitro release of 5-FU and the samples were analyzed spectrophotometrically at 266 nm. Drug release from coated systems depended on the thickness of the mixed film and the composition of the core. Channel formation was initiated in the coat by dissolution of the Eudragit S100 fraction at higher pH in the colonic region. The release was found to be higher in tablets containing Avicel as filler owing to its wicking action compared to that from lactose containing cores. Furthermore, batches containing superdisintegrant (1%, m/m Cross-PVP) along with Avicel in the core released approximately 81.1% drug during the colonic transit time. Kinetic studies indicated that all the formulations followed first-order release kinetics. The developed delivery system will expectedly deliver the drug to the colon.
authors.affiliation: University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh-160014, India.
authors.forename: Ruchita V
authors.initials: RV
authors.lastname: Kumar
authors.forename: Vivek Ranjan
authors.initials: VR
authors.lastname: Sinha
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000737:chemistry* / Q000378:metabolism / Q000627:therapeutic use; D002482:Cellulose / Q000031:analogs & derivatives / Q000032:analysis / Q000737:chemistry; D003106:Colon / Q000378:metabolism*; D015179:Colorectal Neoplasms / Q000188:drug therapy; D003692:Delayed-Action Preparations; D004339:Drug Compounding / Q000379:methods*; D016503:Drug Delivery Systems / Q000379:methods*; D005079:Excipients / Q000737:chemistry; D005472:Fluorouracil / Q000008:administration & dosage / Q000737:chemistry* / Q000378:metabolism / Q000627:therapeutic use; D006244:Hardness; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007785:Lactose / Q000737:chemistry; D010599:Pharmacokinetics; D011109:Polymethacrylic Acids / Q000737:chemistry; D011145:Polyvinyls / Q000737:chemistry; D011312:Pressure; D011759:Pyrrolidines / Q000737:chemistry; D012995:Solubility; D013229:Stearic Acids / Q000737:chemistry; D013607:Tablets / Q000737:chemistry; D013608:Tablets, Enteric-Coated / Q000737:chemistry; D013627:Talc / Q000737:chemistry
chemical_list: D000964:Antimetabolites, Antineoplastic; D003692:Delayed-Action Preparations; D005079:Excipients; D011109:Polymethacrylic Acids; D011145:Polyvinyls; D011759:Pyrrolidines; D013229:Stearic Acids; D013607:Tablets; D013608:Tablets, Enteric-Coated; C505150:poly(N-vinylpyrrolidine); D013627:Talc; C038300:methylmethacrylate-methacrylic acid copolymer; C031183:stearic acid; C013517:ethyl cellulose; D002482:Cellulose; D007785:Lactose; D005472:Fluorouracil